377 related articles for article (PubMed ID: 31043094)
21. Fremanezumab for the prevention of chronic and episodic migraine.
Lionetto L; Cipolla F; Guglielmetti M; Martelletti P
Drugs Today (Barc); 2019 Apr; 55(4):265-276. PubMed ID: 31050694
[TBL] [Abstract][Full Text] [Related]
22. CGRP pathway monoclonal antibodies for cluster headache.
Chan C; Goadsby PJ
Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
[TBL] [Abstract][Full Text] [Related]
23. Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses.
Fiedler-Kelly J; Passarell J; Ludwig E; Levi M; Cohen-Barak O
Headache; 2020 Jul; 60(7):1376-1391. PubMed ID: 32445498
[TBL] [Abstract][Full Text] [Related]
24. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
25. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
[TBL] [Abstract][Full Text] [Related]
26. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.
Melo-Carrillo A; Strassman AM; Nir RR; Schain AJ; Noseda R; Stratton J; Burstein R
J Neurosci; 2017 Nov; 37(44):10587-10596. PubMed ID: 28972120
[TBL] [Abstract][Full Text] [Related]
27. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies.
Negro A; Martelletti P
Expert Rev Neurother; 2019 Aug; 19(8):769-776. PubMed ID: 31109209
[No Abstract] [Full Text] [Related]
28. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
Winner PK; Spierings ELH; Yeung PP; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Headache; 2019 Nov; 59(10):1743-1752. PubMed ID: 31675102
[TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
31. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
[TBL] [Abstract][Full Text] [Related]
32. Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials.
Gao B; Lu Q; Wan R; Wang Z; Yang Y; Chen Z; Wang Z
Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):819-828. PubMed ID: 33136176
[TBL] [Abstract][Full Text] [Related]
33. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
34. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
36. No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.
Blumenfeld AM; Stevanovic DM; Ortega M; Cohen JM; Seminerio MJ; Yang R; Jiang B; Tepper SJ
Headache; 2020 Nov; 60(10):2431-2443. PubMed ID: 33009665
[TBL] [Abstract][Full Text] [Related]
37. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
Diener HC; McAllister P; Jürgens TP; Kessler Y; Ning X; Cohen JM; Campos VR; Barash S; Silberstein SD
Cephalalgia; 2022 Jul; 42(8):769-780. PubMed ID: 35331009
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies for the prevention of migraine.
Raffaelli B; Neeb L; Reuter U
Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
[No Abstract] [Full Text] [Related]
40. Fremanezumab autoinjector pen for the prevention of migraine.
Weatherall MW
Ther Deliv; 2021 Sep; 12(9):645-650. PubMed ID: 34392708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]